アベルマブとアキシチニブを一次治療として投与された日本人腎細胞癌患者における現在の治療成績：後向き研究（J-DART）

基本情報

NCT ID

NCT05012865

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

48

治験依頼者名

Pfizer

概要

This study is a multicenter, non-interventional, retrospective, medical chart review of patients with metastatic renal cell cancer(mRCC) treated with avelumab plus axitinib as a first-line therapy in Japan between 20 December 2019 and 20 December 2020. All decisions regarding clinical management and treatment of the participating patients were made by the investigator as part of standard care in real-world clinical setting and were not contingent upon the patient's participation in the study. Data will be collected if available per study site.

対象疾患

介入

依頼者（Sponsor）

実施施設 (12)